Meeting
2019 ASCO Annual Meeting
Race and response to neoadjuvant chemotherapy according to MammaPrint risk.
Authors
Raquel Nunes
Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD
Raquel Nunes , Femke De Snoo , Lisette Stork-Sloots , Hong-Khanh (Tina) Dinh Treece , Christa Dreezen , M. William Audeh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT01479101
Citation
J Clin Oncol 37, 2019 (suppl; abstr 578)
DOI
10.1200/JCO.2019.37.15_suppl.578
Abstract #
578
Poster Bd #
70
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST.
First Author: Peter D. Beitsch
Poster
2016 ASCO Annual Meeting
Investigating denosumab as add-on neoadjuvant treatment for hormone receptor-negative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX).
First Author: Sherko Kümmel
First Author: Jose Pacheco
Poster
2011 ASCO Annual Meeting
RNA-based molecular tumor typing and immunological infiltrate as response predictors to neoadjuvant chemotherapy: Prospective validation in the GeparQuinto-PREDICT substudy.
First Author: C. Denkert